Sartorius Stedim Biotech, a global leader in biopharmaceutical process solutions, has entered into a strategic partnership with Nanotein Technologies, an innovator in next-generation immune cell activation reagents. As part of the agreement, Sartorius will invest up to USD 3 million for a minority stake in Nanotein Technologies, supporting the commercialization and co-development of solutions powered by Nanotein’s proprietary NanoSpark® platform.
Under an exclusive global distribution arrangement, Sartorius will make Nanotein’s flagship products—NanoSpark® STEM-T Soluble T Cell Activator and NanoSpark® GROW-NK Soluble Activator—available to customers worldwide. These advanced reagents are engineered to boost the expansion and yield of T cells and natural killer (NK) cells, two critical immune cell types that form the backbone of modern cell therapy applications, including CAR-T and NK-based cancer treatments.
Also Read: Altasciences & VoxCell Partner to Boost Drug Development
Efficient manufacturing of cell therapies relies on the activation and expansion of immune cells to produce large quantities of high-quality cells. Traditional methods often face hurdles such as dependence on feeder cells or inconsistent yields. “Nanotein’s soluble activators are designed to improve cell therapy expansion by enhancing the quality and quantity of T cells and providing a feeder-free soluble activator for NK cell activation and expansion, addressing critical challenges in the manufacturing process,” said Curtis Hodge, Co-Founder and CEO of Nanotein Technologies.
“This partnership will provide our customers with access to some of the most promising new tools for simplifying workflows and thus improving immune cell manufacturing,” said René Fáber, CEO of Sartorius Stedim Biotech. “Together with Nanotein, we’re enabling cell therapy manufacturers to innovate with greater speed and confidence – from early process development to the clinic.”
Beyond product distribution, Sartorius and Nanotein will jointly leverage the NanoSpark® platform to develop new and innovative solutions tailored to the rapidly growing cell and gene therapy market, helping advance breakthroughs from research to commercial-scale manufacturing.